Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a 12 month low of $0.01 and a 12 month high of $1.99. The stock has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.